Innovative Research

We are committed to addressing global health needs and improving standards of care by leveraging our expertise and resources.

AbbVie scientists in North Chicago collaborate to address neglected diseases.

Developing Medicines That Benefit Patients

Our research and innovation focuses on developing medicines that deliver strong clinical performance, provide more patient benefit and deliver economic value—especially where there is significant need around the world in certain disease areas. This includes immunology, kidney disease, liver disease, neuroscience and oncology.

Collaborating with Health Care Professionals to Treat the Most Pressing Medical Conditions

Our collaborations help us improve existing products and deliver innovation in patient care. We work with health care professionals in the research and development process and in medical education. Their expertise helps us develop and enhance products and therapies to treat conditions such as HIV, arthritis, immunological and metabolic disorders, and cancer.

Solving Neglected Tropical Diseases

We are working to address neglected diseases that disproportionally impact the world’s poor and marginalized populations. In 2018 more than 400 of our most experienced scientists dedicated nearly 40,000 pro-bono hours to drug development projects, advisory boards and compound screening to help solve neglected diseases. We also provide a large library of diverse compounds to screen against many neglected disease.

AbbVie supports the London Declaration on Neglected Tropical Diseases, a commitment to efforts to control, eliminate or eradicate 10 diseases by 2020. Our Executive Council on Neglected Diseases coordinates efforts across the company to contribute our scientific expertise and philanthropic support to address neglected diseases.

Our NTD Partners

DNDi is a nonprofit drug research and development organization that is developing new treatments for neglected diseases. Our partnership supplies thousands of our compounds to be screened for activity against leishmania, Chagas disease and helminth infections. Our relationship expanded in 2012 to include a four-year joint research and nonexclusive licensing agreement. This provides DNDi access to selected classes of AbbVie’s proprietary molecules, identified from the above screens, and accompanying data to guide the search for improved treatments. Any products developed as a result of this partnership are provided to endemic countries by DNDi at the lowest sustainable price to ensure the greatest patient access

As a founding member of TBDA, AbbVie has provided over 100,000 of our compounds for screening against replicating tuberculosis (TB). Active compounds from these screens are shared within the consortium to speed the identification of the most promising approaches to shorten and improve the quality of TB therapy. Our scientists are very engaged with this partnership, providing cheminformatics support and characterizing lead compounds from other TBDA partners in addition to the above screening activities.

AbbVie scientists provide technical consulting through the TB Alliance Scientific Advisory Council, while new compounds are synthesized at AbbVie and then screened against both replicating and latent TB at the University of Illinois, Chicago.

AbbVie is working closely with MMV to support two preclinical development programs of novel antimalarials.

We work with leading research institutions, including Liverpool School of Tropical Medicine (Anti-Wolbachia Consortium), University of Washington, University of Sussex and University of Dundee (Drug Discovery Unit) on NTD screening and research. In addition, we provide laboratory facilities and mentor student interns under a program sponsored by Franciscan University of Steubenville (Franciscan Institute for World Health).

Through our sponsorship of the Brazilian Scientific Mobility program, AbbVie employees mentor students, sharing their expertise with the next generation of innovators. The program grants Brazilian students opportunities to study STEM fields in the United States and promotes knowledge sharing and capacity building by investing in future leaders.In Argentina, AbbVie has partnered with the Ministry of Health of Jujuy since 2012.

The AbbVie Foundation, a nonprofit charitable organization, supports advancing progress against NTDs. Its grants support organizations including the University of Notre Dame and MAP International, helps prevent and treat NTDs in Bolivia, the Ivory Coast and Haiti. In the Ivory Coast, a three-year partnership with MAP International is helping to treat Buruli ulcer (a severe skin ulceration) through education campaigns, health care professional training and treatment.